Authors
Fabian J Brunner, Christoph Waldeyer, Francisco Ojeda, Veikko Salomaa, Frank Kee, Susana Sans, Barbara Thorand, Simona Giampaoli, Paolo Brambilla, Hugh Tunstall-Pedoe, Marie Moitry, Licia Iacoviello, Giovanni Veronesi, Guido Grassi, Ellisiv B Mathiesen, Stefan Söderberg, Allan Linneberg, Hermann Brenner, Philippe Amouyel, Jean Ferrières, Abdonas Tamosiunas, Yuriy P Nikitin, Wojciech Drygas, Olle Melander, Karl-Heinz Jöckel, David M Leistner, Jonathan E Shaw, Demosthenes B Panagiotakos, Leon A Simons, Maryam Kavousi, Ramachandran S Vasan, Robin PF Dullaart, S Goya Wannamethee, Ulf Risérus, Steven Shea, James A de Lemos, Torbjørn Omland, Kari Kuulasmaa, Ulf Landmesser, Stefan Blankenberg, Tanja Zeller, Jukka Kontto, Satu Männistö, Andres Metspalu, Karl Lackner, Philipp Wild, Annette Peters, Christa Meisinger, Chiara Donfrancesco, Stefano G Signorini, Maris Alver, Mark Woodward, Francesco Gianfagna, Simona Costanzo, Tom Wilsgaard, Mats Eliasson, Torben Jørgensen, Henry Völzke, Marcus Dörr, Matthias Nauck, Ben Schöttker, Thiess Lorenz, Nataliya Makarova, Raphael Twerenbold, Jean Dallongeville, Annette Dobson, Sofia Malyutina, Andrzej Pajak, Gunnar Engström, Martin Bobak, Börge Schmidt, Tuija Jääskeläinen, Teemu Niiranen, Pekka Jousilahti, Graham Giles, Allison Hodge, Jens Klotsche, Dianna J Magliano, Magnus N Lyngbakken, Kristian Hveem, Christos Pitsavos, Emelia J Benjamin, Stephan JL Bakker, Peter Whincup, M Kamran Ikram, Martin Ingelsson, Wolfgang Koenig
Publication date
2019/12/14
Journal
The Lancet
Volume
394
Issue
10215
Pages
2173-2183
Publisher
Elsevier
Description
Background
The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment.
Methods
In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic …
Scholar articles
FJ Brunner, C Waldeyer, F Ojeda, V Salomaa, F Kee… - The Lancet, 2019